NEXT BIOTECH

We are Rolling the Dice on this One…

Long term Creso Pharma (ASX: CPH) shareholders have had a rough ride in the last 12 months. Last week the $20M capped CPH raised circa A$9M at $0.0291 per share, finally extinguishing the company’s debt and ridding the company of major con note holders that were hampering any share price appreciation.

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.

Can This ASX Junior Surge Through the Pain Barrier?

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

CPH Kick Start African Launch - $300k Order Values Confirmed

Creso Pharma (ASX:CPH | FRA:1X8) has announced that through Pharma Dynamics, Creso’s partner in the African region, initial orders worth approximately A$300,000 for the cannaQIX® product range have been made.

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.

Thanks for subscribing!

X